Of note, this cannot be explained by differences in follow-up time, as this was similar in anti-CCAR1–positive and anti-CCAR1–negative cancer-free patients in both cohorts (Johns Hopkins cohort, median follow-up 8 years in anti-CCAR1–negative patients, 10 years in anti-CCAR1–positive; Stanford cohort, median follow-up 9 years in anti-CCAR1–negative patients, 10 years in anti-CCAR1–positive). Here, CCAR1 is linked to cancer.